Abstract

Thrombotic events are common complications in COVID-19 patients that include both thrombus formation in large vessels and the microvasculature of the lung and other organs. COVID-19-associated coagulopathy (CAC) and disseminated intravascular coagulation (DIC) have similarities and differences, and whether CAC is a form of DIC is the subject of debate. Reported mechanisms of CAC include activated coagulation, endotheliopathy, up-regulated innate and adaptive immunity, and activated complement system. Although the clinical features and laboratory findings of CAC and DIC seem different, there are fundamental similarities that should be considered. Basically, the pathological findings of COVID-19 fall within the scope of the definition of DIC, i.e., systemic activation of coagulation caused by or resulting from the microvascular damage. Therefore, we suggest that although CAC differs from usual infection-associated DIC, its various features indicate that it can be considered a thrombotic phenotype DIC. This review summarizes the current knowledge about CAC including differences and similarities with sepsis-associated DIC.

Highlights

  • COVID-19 is known to be frequently associated with coagulopathy and thrombotic complications

  • An initial report of COVID-19 patients with acute respiratory failure noted the development of disseminated intravascular coagulation (DIC) according to International Society on Thrombosis and Haemostasis (ISTH) criteria [1], with the incidence of DIC in non-survivors much higher than that in survivors (71.4% vs. 0.6%, respectively) [2]

  • Sepsis following an acute infection can be complicated by DIC

Read more

Summary

Introduction

COVID-19 is known to be frequently associated with coagulopathy and thrombotic complications. Recent studies suggest the mechanisms of bacterial sepsis-induced coagulopathy (SIC) and that of CAC are different and more complicated in CAC [4]. The fundamental concept of DIC, as proposed by the ISTH in 2001 [1], is “an acquired syndrome characterized by the intravascular activation of coagulation with loss of localization arising from different causes. It can originate from and cause damage to the microvasculature, which, if sufficiently severe, can.

Thefrom progression from COVID‐19‐associated disseminated intravascular
Characteristic Differences between
Endothelial and Damage
Coagulation and Fibrinolytic Systems in Infection
Innate Immune System
Adaptive Immune System
Complement System
Diagnosis of CAC and DIC
Skin and Acral Lesions
Anticoagulant Therapy Using Heparin for CAC and DIC
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.